Effectiveness of G-CSF in chemotherapy for digestive system tumors: a systematic review of the Clinical Practice Guidelines for the Use of G-CSF 2022 delineated by the Japan Society of Clinical Oncology

被引：0

作者：

Ito, Mamoru ^{[1
]}

Okumura, Yuta ^{[2
]}

Nio, Kenta ^{[3
]}

Baba, Eishi ^{[4
]}

Ozaki, Yukinori ^{[5
]}

Nishio, Hiroshi ^{[6
]}

Ichihara, Eiki ^{[7
]}

Miura, Yuji ^{[8
]}

Endo, Makoto ^{[9
]}

Yano, Shingo ^{[10
]}

Maruyama, Dai ^{[11
]}

Yoshinami, Tetsuhiro ^{[12
]}

Susumu, Nobuyuki ^{[13
]}

Takekuma, Munetaka ^{[14
]}

Motohashi, Takashi ^{[15
]}

Ochi, Nobuaki ^{[16
]}

Kubo, Toshio ^{[17
]}

Uchino, Keita ^{[18
]}

Kimura, Takahiro ^{[19
]}

Kamiyama, Yutaro ^{[20
]}

Nakao, Shinji ^{[21
]}

Tamura, Shinobu ^{[22
]}

Nishimoto, Hitomi ^{[23
]}

Kato, Yasuhisa ^{[24
]}

Sato, Atsushi ^{[25
]}

Takano, Toshimi ^{[5
]}

Tsuchihashi, Kenji ^{[1
]}

机构：

[1] Kyushu Univ Hosp, Dept Hematol Oncol & Cardiovasc Med, 3-1-1 Maidashi,Higashi ku, Fukuoka 8128582, Japan

[2] NHO Kyushu Canc Ctr, Dept Gastrointestinal & Med Oncol, Fukuoka, Japan

[3] Hamanomachi Hosp, Dept Med Oncol, Fukuoka, Japan

[4] Kyushu Univ, Grad Sch Med Sci, Dept Oncol & Social Med, Fukuoka, Japan

[5] Japanese Fdn Canc Res, Dept Breast Med Oncol, Canc Inst Hosp, Tokyo, Japan

[6] Keio Univ, Sch Med, Dept Obstet & Gynecol, Tokyo, Japan

[7] Okayama Univ Hosp, Ctr Clin Oncol, Okayama, Japan

[8] Toranomon Gen Hosp, Dept Med Oncol, Tokyo, Japan

[9] Kyushu Univ, Dept Orthopaed Surg, Fukuoka, Japan

[10] Jikei Univ, Sch Med, Dept Internal Med, Div Clin Oncol Hematol, Tokyo, Japan

[11] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Hematol Oncol, Tokyo, Japan

[12] Osaka Univ, Grad Sch Med, Dept Breast & Endocrine Surg, Osaka, Japan

[13] Int Univ Hlth & Welf, Narita Hosp, Dept Obstet & Gynecol, Chiba, Japan

[14] Shizuoka Canc Ctr, Dept Gynecol, Shizuoka, Japan

[15] Tokyo Womens Med Univ Hosp, Dept Obstet & Gynecol, Tokyo, Japan

[16] Kawasaki Med Sch, Dept Gen Internal Med 4, Okayama, Japan

[17] Okayama Univ Hosp, Dept Allergy & Resp Med, Okayama, Japan

[18] NTT Med Ctr Tokyo, Dept Med Oncol, Tokyo, Japan

[19] Jikei Univ, Sch Med, Dept Urol, Tokyo, Japan

[20] Jikei Univ, Sch Med, Dept Clin Oncol Hematol, Tokyo, Japan

[21] Kanazawa Univ, Inst Med Pharmaceut & Hlth Sci, Fac Med, Dept Hematol, Kanazawa, Ishikawa, Japan

[22] Wakayama Med Univ, Dept Hematol Oncol, Wakayama, Japan

[23] Okayama Univ Hosp, Dept Nursing, Okayama, Japan

[24] Shonan Univ Med Sci, Fac Pharmaceut Sci, Dept Drug Informat, Kamakura, Kanagawa, Japan

[25] Hirosaki Univ, Grad Sch Med, Dept Med Oncol, Aomori, Japan

来源：

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 29卷 / 06期

关键词：

G-CSF; Febrile neutropenia; Digestive system tumor; FEBRILE NEUTROPENIA; 1ST-LINE TREATMENT; PLUS CHEMOTHERAPY; OPEN-LABEL; PHASE-III; CANCER; RECOMMENDATIONS; PEGFILGRASTIM; FOLFIRINOX; GEMCITABINE;

D O I：

10.1007/s10147-024-02502-6

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

BackgroundGranulocyte colony-stimulating factor (G-CSF) reportedly reduces the risk of neutropenia and subsequent infections caused by cancer chemotherapy. Although several guidelines recommend using G-CSF in primary prophylaxis according to the incidence rate of chemotherapy-induced febrile neutropenia (FN), the effectiveness of G-CSF in digestive system tumor chemotherapy remains unclear. To address these clinical questions, we conducted a systematic review as part of revising the Clinical Practice Guidelines for the Use of G-CSF 2022 published by the Japan Society of Clinical Oncology.MethodsThis systematic review addressed two main clinical questions (CQ): CQ1: "Is primary prophylaxis with G-CSF effective in chemotherapy?", and CQ2: "Is increasing the intensity of chemotherapy with G-CSF effective?" We reviewed different types of digestive system tumors, including esophageal, gastric, pancreatic, biliary tract, colorectal, and neuroendocrine carcinomas. PubMed, Cochrane Library, and Ichushi-Web databases were searched for information sources. Independent systematic reviewers conducted two rounds of screening and selected relevant records for each CQ. Finally, the working group members synthesized the strength of evidence and recommendations.ResultsAfter two rounds of screening, 5/0/3/0/2/0 records were extracted for CQ1 of esophageal/gastric/pancreatic/biliary tract/colorectal/ and neuroendocrine carcinoma, respectively. Additionally, a total of 2/6/1 records were extracted for CQ2 of esophageal/pancreatic/colorectal cancer, respectively. The strength of evidence and recommendations were evaluated for CQ1 of colorectal cancer; however, we could not synthesize recommendations for other CQs owing to the lack of records.ConclusionThe use of G-CSF for primary prophylaxis in chemotherapy for colorectal cancer is inappropriate.

引用

页码：689 / 699

页数：11

共 50 条

[21] THE USE OF G-CSF FOR IMPLANTATION FAILURE IN IVF: A CLINICAL TRIAL
Scarpellini, F.
Sbracia, M.
FERTILITY AND STERILITY, 2011, 96 (03) : S93 - S93
[22] Clinical use of recombinant G-CSF in neonatal sepsis with neutropenia
Corona, G
Liotta, C
Gitto, E
Cordaro, V
Barberi, I
PEDIATRIC RESEARCH, 1999, 45 (05) : 762 - 762
[23] G-CSF AND G-CSF BIOSIMILARS: A META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS IN BREAST CANCER PATIENTS UNDERGOING MYELOSUPPRESSIVE CHEMOTHERAPY
Curigliano, Giuseppe
Botteri, Edoardo
Krendyukov, Andriy
BREAST, 2017, 36 : S69 - S69
[24] A prospective observational study to evaluate G-CSF usage in patients with solid tumors receiving myelosuppressive chemotherapy in Italian clinical oncology practice
Barni, S.
Lorusso, V.
Giordano, M.
Sogno, G.
Gamucci, T.
Santoro, A.
Passalacqua, R.
Iaffaioli, V.
Zilembo, N.
Mencoboni, M.
Roselli, M.
Pappagallo, G.
Pronzato, P.
MEDICAL ONCOLOGY, 2014, 31 (01)
[25] A prospective observational study to evaluate G-CSF usage in patients with solid tumors receiving myelosuppressive chemotherapy in Italian clinical oncology practice
S. Barni
V. Lorusso
M. Giordano
G. Sogno
T. Gamucci
A. Santoro
R. Passalacqua
V. Iaffaioli
N. Zilembo
M. Mencoboni
M. Roselli
G. Pappagallo
P. Pronzato
Medical Oncology, 2014, 31
[26] New European guidelines for the use of G-CSF for chemotherapy-induced neutropenia
Nature Clinical Practice Oncology, 2006, 3 (11): : 589 - 589
[27] Effectiveness and safety of primary prophylaxis of granulocyte colony-stimulating factor during dose-dense chemotherapy for urothelial cancer: Clinical Practice Guidelines for the Use of G-CSF 2022
Keita Uchino
Shingo Tamura
Shoji Kimura
Keisuke Shigeta
Takahiro Kimura
Yukinori Ozaki
Hiroshi Nishio
Kenji Tsuchihashi
Eiki Ichihara
Makoto Endo
Shingo Yano
Dai Maruyama
Tetsuhiro Yoshinami
Nobuyuki Susumu
Munetaka Takekuma
Takashi Motohashi
Mamoru Ito
Eishi Baba
Nobuaki Ochi
Toshio Kubo
Yutaro Kamiyama
Shinji Nakao
Shinobu Tamura
Hitomi Nishimoto
Yasuhisa Kato
Atsushi Sato
Toshimi Takano
Yuji Miura
International Journal of Clinical Oncology, 2024, 29 : 545 - 550
[28] Effectiveness and safety of primary prophylaxis of granulocyte colony-stimulating factor during dose-dense chemotherapy for urothelial cancer: Clinical Practice Guidelines for the Use of G-CSF 2022
Uchino, Keita
Tamura, Shingo
Kimura, Shoji
Shigeta, Keisuke
Kimura, Takahiro
Ozaki, Yukinori
Nishio, Hiroshi
Tsuchihashi, Kenji
Ichihara, Eiki
Endo, Makoto
Yano, Shingo
Maruyama, Dai
Yoshinami, Tetsuhiro
Susumu, Nobuyuki
Takekuma, Munetaka
Motohashi, Takashi
Ito, Mamoru
Baba, Eishi
Ochi, Nobuaki
Kubo, Toshio
Kamiyama, Yutaro
Nakao, Shinji
Tamura, Shinobu
Nishimoto, Hitomi
Kato, Yasuhisa
Sato, Atsushi
Takano, Toshimi
Miura, Yuji
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2024, 29 (05) : 545 - 550
[29] The clinical observation of G-CSF used in supplementary chemotherapy of cancer patients.
Zhao, Z
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 191S - 191S
[30] Evaluating risk of hospitalization with G-CSF use in real-world oncology practice
Tan, H.
Tomic, K.
Daniel, G.
Hurley, D.
Barron, R.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)

← 1 2 3 4 5 →